Scholarlink

Background <p>Lung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing accurate and practical prognostic tools is essential to optimize treatment decision-making.</p> Methods <p>This retrospective study analyzed 436 lung cancer patients treated with ICIs, who were randomly divided into training (70%) and validation (30%) cohorts. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using LASSO regression and multivariate Cox regression. Nomograms were constructed based on clinical and blood biomarkers. Model performance was assessed using the concordance index (C-index), ROC curve, calibration curve, and decision curve analysis (DCA). Kaplan–Meier analysis validated patient stratification.</p> Results <p>The key independent predictive factors for OS and PFS included neutrophil-to-lymphocyte ratio (NLR), previous surgery, liver metastasis, clinical stage, treatment lines, and treatment response evaluation. The nomograms achieved C-index values of 0.709 (OS) and 0.730 (PFS) in the training cohort, with validation C-indexes of 0.655 (OS) and 0.694 (PFS). The ROC curves demonstrated good predictive accuracy for 12-, 24-, and 36-month outcomes. High-risk patients exhibited significantly shorter median OS and PFS (<i>P</i> &lt; 0.001).</p> Conclusion <p>The nomograms developed in this study, integrating clinical and blood biomarkers, provide a cost-effective, simple, and accurate tool for predicting the prognosis of lung cancer patients receiving ICIs treatment, to facilitate personalized clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Ting Ouyang,
  • Fei Zhang,
  • Yan Yang,
  • Tianwei Luo,
  • Ao Chen,
  • Ning Han,
  • Jun Qian,
  • Xiaoyuan Chu,
  • Chao Chen,
  • Mi Yang

摘要

Background

Lung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing accurate and practical prognostic tools is essential to optimize treatment decision-making.

Methods

This retrospective study analyzed 436 lung cancer patients treated with ICIs, who were randomly divided into training (70%) and validation (30%) cohorts. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using LASSO regression and multivariate Cox regression. Nomograms were constructed based on clinical and blood biomarkers. Model performance was assessed using the concordance index (C-index), ROC curve, calibration curve, and decision curve analysis (DCA). Kaplan–Meier analysis validated patient stratification.

Results

The key independent predictive factors for OS and PFS included neutrophil-to-lymphocyte ratio (NLR), previous surgery, liver metastasis, clinical stage, treatment lines, and treatment response evaluation. The nomograms achieved C-index values of 0.709 (OS) and 0.730 (PFS) in the training cohort, with validation C-indexes of 0.655 (OS) and 0.694 (PFS). The ROC curves demonstrated good predictive accuracy for 12-, 24-, and 36-month outcomes. High-risk patients exhibited significantly shorter median OS and PFS (P < 0.001).

Conclusion

The nomograms developed in this study, integrating clinical and blood biomarkers, provide a cost-effective, simple, and accurate tool for predicting the prognosis of lung cancer patients receiving ICIs treatment, to facilitate personalized clinical decision-making.